FGP
TVTX icon

Freestone Grove Partners’s Travere Therapeutics TVTX Stock Holding History

Freestone Grove Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
4,294
+570
+15% +$25.3K ﹤0.01% 784
2026
Q1 		$111K Buy
+3,724
New +$111K ﹤0.01% 796
2025
Q1 		– Sell
-25,521
Closed -$445K – 796
2024
Q4 		$445K Buy
+25,521
New +$451K 0.01% 396

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Freestone Grove Partners's TVTX Position: Q2 2026 in Review

Freestone Grove Partners increased its Travere Therapeutics (TVTX) stake by 15% in Q2 2026, buying an estimated $25.3K and bringing the position to 4,294 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #784.

Freestone Grove Partners first reported a position in TVTX in Q4 2024 and has held it in 3 quarters since. The position peaked at $445K in Q4 2024. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Freestone Grove Partners held 4,294 shares of Travere Therapeutics worth $244K as of Q2 2026.
  • Freestone Grove Partners bought 570 Travere Therapeutics shares in Q2 2026, an estimated $25.3K.
  • Travere Therapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #784 holding.
  • Freestone Grove Partners first reported a position in Travere Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Freestone Grove Partners's Travere Therapeutics position peaked at $445K in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.